Drug Trial Radar · NCT04848493
National Project on Vaccines, COVID-19 and Frail Patients
Last checked: Nov 19, 2026Latest source record: Jun 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
747
Actual
Start
Apr 19, 2021
Primary completion
May 16, 2022
Study completion Dec 31, 2022
Sponsor
- Lead sponsor
- Azienda USL Reggio Emilia - IRCCSGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- Collaborators
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano; Istituto Clinico Humanitas; IRCCS San Raffaele; Regina Elena Cancer Institute; Istituto Nazionale per le Malattie Infettive "Lazzaro Spallanzani" IRCCS; University of Roma La Sapienza; Fondazione IRCCS Policlinico San Matteo di Pavia; Istituti Fisioterapici Ospitalieri; Istituti Tumori Giovanni Paolo II; Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta; IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy; IRCCS Azienda Ospedaliero-Universitaria di Bologna
- First posted
- Apr 19, 2021
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicentre observational study with the aim of evaluating the antibody and cellular response after vaccination for SARS-CoV-2 with Pfizer-BioNTech or Moderna vaccines in frail subjects with impaired immuno-competence, due to their underlying diseases or ongoing therapies.
Conditions
- COVID-19
- Solid Tumor
- Hematologic Diseases
- Neurologic Disorder
- Rheumatic Diseases
Interventions
COVID-19 vaccinesBiological
This is an observational prospective study whose general objective is to assess the impact of COVID-19 vaccination in terms of induction of humoral and cell-mediated immune responses in selected fragile (altered immunocompetence) populations.
Primary outcomes
What the sponsor says the trial is designed to measure.
- SARS-CoV-2 vaccine immunizationTime frame: 5-7 weeks after T0 for Pfizer/BioNTech vaccination; 6-8 weeks after T0 for Moderna vaccination
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
IRCCS Istituto Tumori Giovanni Paolo II
Bari, Bari, Italy
IRCCS Azienda Ospedaliera Universitaria
Bologna, Bologhna, Italy
Ospedale Policlinico San Martino IRCCS
Genova, Genova, Italy
Foindazione IRCCS Istituto Neurologico Carlo Besta
Milan, Milano, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Milano, Italy
IRCCS Istituto Clinico Humanitas
Milan, Milano, Italy
IRCCS Ospedale San Raffaele
Milan, Milano, Italy
Fondazione IRCCS Policlinico San Matteo
Pavia, Pavia, Italy
Azienda USL IRCCS di Reggio Emilia
Reggio Emilia, Reggio Emilia, Italy
IRCCS Istituto Nazionale Tumori Regina Elena
Roma, Roma, Italy
IRCCS Istituto per le Malattie Infettive Lazzaro Spallanzani
Roma, Roma, Italy
Istituto Dermatologico San Gallicano
Roma, Roma, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.